Rujimongkon K et al., 2026: Follow-up in vitro study from the same Bangkok group reporting that ivermectin suppresses oestrogen-induced proliferation and downregulates ER, HER2 and TGF-beta pathway markers in endocrine-resistant breast cancer cells, building on their earlier Wnt findings.
Our previous work showed that IVM inhibited cell proliferation and invasion in breast cancer cells, primarily through modulation of the Wnt signaling pathway.
n/a (HTML full text)
Rujimongkon K et al., 2026: Follow-up in vitro study from the same Bangkok group reporting that ivermectin suppresses oestrogen-induced proliferation and downregulates ER, HER2 and TGF-beta pathway markers in endocrine-resistant breast cancer cells, building on their earlier Wnt findings. Study type: cell lines only. N: n/a. Country: Thailand (Chulalongkorn University). Dose: in vitro concentrations, not stated in the abstract. Funder: not stated. Declared COI: 'The authors have declared that no competing interests exist.' Comparator: vehicle/untreated cells. This is a 2026 confirmation of the group's Wnt-linked results. Study type: lab.
